The effect of simvastatin on the expression of high mobility group box-1 protein in atherosclerotic rats

Chinese Critical Care Medicine

Volumn 22, Issue 5, 2010, Pages 306-308

  Yin, Ya Xin ^a   Yao, Yong Ming ^a   Liu, Run Mei ^a   Zhai, Hong Xia ^a   Li, Liang ^a   Zhang, Jin Jin ^a   Chen, Hai Wei ^a   Wang, Lei ^a   Li, Na ^a   Xia, Yun Feng ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Atherosclerosis; High mobility group box 1 protein; Plaque; Simvastatin

Indexed keywords

COLECALCIFEROL; HIGH MOBILITY GROUP B1 PROTEIN; MESSENGER RNA; SIMVASTATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA ATHEROSCLEROSIS; AORTA WALL; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; LIPID DIET; NONHUMAN; PROTEIN EXPRESSION; RAT; TREATMENT DURATION; UPREGULATION;

ANIMALS; ATHEROSCLEROSIS; DISEASE MODELS, ANIMAL; HMGB1 PROTEIN; MALE; PLAQUE, ATHEROSCLEROTIC; RANDOM ALLOCATION; RATS; RATS, WISTAR; RNA, MESSENGER; SIMVASTATIN;

EID: 77953573493     PISSN: 10030603     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.1003-0603.2010.05.016     Document Type: Article

References (16)

1. Kalinina N, Agrotis A, Antropova Y, et al. Increased expression of the DNA-binding cytokine HMGB-1 in human atherosclerotic lesions, role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol, 2004, 24:2320-2325.
2. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA, 1986, 256:2823-2828.
3. Shephered J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med, 1995, 333:1301-1307.
4. Scandinavian Simvastatin Surivival Study Group. Randomised trial of cholesterol lowering in 4 444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet, 1994, 344:1383-1389.
5. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med, 1998, 339:1349-1357.
6. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation, 1994, 89:2519-2524. (Pubitemid 24979884)
7. Andersson U, Tracey KJ. HMGB1 as a mediator of necrosis-induced inflammation and a therapeutic target in arthritis. Rheum Dis Clin North Am, 2004, 30:627-637. (Pubitemid 38917005)
8. Erlandsson Harris H, Andersson U. Mini-review, the nuclear protein HMGB1 as a proinflammatory mediator. Eur J Immunol, 2004, 34:1503-1512.
9. Chen G, Ward MF, Sama AE, et al. Extracellular HMGB1 as a proinflammatory cytokine. J Interferon Cytokine Res, 2004, 24:329-333.
10. Inoue K, Kawahara K, Biswas KK, et al. HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Pathol, 2007, 16:136-143.
11. Porto A, Palumbo R, Pieroni M, et al. Smooth muscle cells in human atherosclerotic plaques secrete and proliferate in response to high mobility group box 1 protein. FASEB J, 2006, 20:2565-2566.
12. Yamada S, Yakabe K, Ishii J, et al. New high mobility group box 1 assay system. Clin Chim Acta, 2006, 372:173-178. (Pubitemid 44286776)
13. Dupuis J, Tardif JC, Cernacek P, et al. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation, 1999, 99:3227-3233. (Pubitemid 29293431)